Search Results - "Ndife, Briana"
-
1
Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study
Published in Future oncology (London, England) (01-09-2019)“…Targeted therapy (TT) and immuno-oncology (IO) drugs are approved for patients with BRAF mutant metastatic melanoma (MM). We compared real-world outcomes for…”
Get full text
Journal Article -
2
Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States
Published in PharmacoEconomics (01-02-2019)“…Objectives The aim of this study was to assess the cost effectiveness of midostaurin + cytarabine + daunorubicin (midostaurin arm) versus placebo + cytarabine…”
Get full text
Journal Article -
3
Development and testing of an alternative responder definition for EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI)
Published in Rheumatic & musculoskeletal diseases open (01-03-2023)“…ObjectivesDryness, fatigue and joint/muscle pain are typically assessed in Sjögren’s trials using European Alliance of Associations for Rheumatology Sjögren’s…”
Get full text
Journal Article -
4
1234 Thrombotic microangiopathy (TMA) response during index atypical haemolytic uremic syndrome (aHUS) hospitalisation
Published in Nephrology, dialysis, transplantation (23-05-2024)Get full text
Journal Article -
5
Atypical Hemolytic Uremic Syndrome (aHUS) Clinical Characteristics and Treatment Patterns Associated with Readmission after Index Hospitalization
Published in Blood (02-11-2023)“…Introduction Atypical hemolytic uremic syndrome (aHUS) is associated with dysregulation of the alternative complement pathway and causes significant morbidity…”
Get full text
Journal Article -
6
-
7
-
8
Atypical Hemolytic Uremic Syndrome (aHUS) Clinical Characteristics Associated with Renal Replacement Therapy (RRT) Initiation During Index Hospitalization and RRT Requirement After Discharge: SA-PO795
Published in Journal of the American Society of Nephrology (01-11-2023)Get full text
Journal Article -
9
5665 C3 GLOMERULOPATHY CURRENT THERAPY AND REAL-WORLD MANAGEMENT - INTERIM RESULTS FROM A MULTI-COUNTRY STUDY
Published in Nephrology, dialysis, transplantation (14-06-2023)Get full text
Journal Article -
10
-
11
-
12
-
13
-
14
C3 Glomerulopathy Current Treatment Options and Real-World Management: Results from a Multi-Country Study: SA-PO916
Published in Journal of the American Society of Nephrology (01-11-2023)Get full text
Journal Article -
15
Real-World Time to Diagnosis in C3 Glomerulopathy (C3G): TH-PO647
Published in Journal of the American Society of Nephrology (01-11-2023)Get full text
Journal Article -
16
-
17
Patient preferences for treatment of metastatic melanoma
Published in Future oncology (London, England) (01-04-2019)“…To investigate patient preferences for clinical attributes of first-line metastatic melanoma treatments. A discrete-choice experiment and best-worst scaling…”
Get full text
Journal Article -
18
2632 Quality of life and fatigue burden in individuals living with Complement 3 Glomerulopathy – a real-world study
Published in Nephrology, dialysis, transplantation (23-05-2024)Get full text
Journal Article -
19
Characteristics of Patients with Complement 3 Glomerulopathy (C3G) in a US Multi-Center Assessment: TH-PO642
Published in Journal of the American Society of Nephrology (01-11-2023)Get full text
Journal Article -
20